Cargando…
Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence
Cardiovascular diseases and cancer are the most common death causes in the USA and Europe. Moreover, many patients suffer from both of these conditions – a situation which may result from cardiotoxicity of anticancer treatment. In order to reduce the severity of this adverse effect, various methods...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743633/ https://www.ncbi.nlm.nih.gov/pubmed/31564887 http://dx.doi.org/10.2147/TCRM.S215857 |
_version_ | 1783451303651835904 |
---|---|
author | Korzeniowska, Katarzyna Jankowski, Jerzy Cieślewicz, Artur Jabłecka, Anna |
author_facet | Korzeniowska, Katarzyna Jankowski, Jerzy Cieślewicz, Artur Jabłecka, Anna |
author_sort | Korzeniowska, Katarzyna |
collection | PubMed |
description | Cardiovascular diseases and cancer are the most common death causes in the USA and Europe. Moreover, many patients suffer from both of these conditions – a situation which may result from cardiotoxicity of anticancer treatment. In order to reduce the severity of this adverse effect, various methods have been proposed, including the usage of new drug forms and less toxic analogs, omitting the combinations of potentially cardiotoxic drugs and introducing potential cardioprotective agents to the therapy. However, prevention of cardiotoxicity still seems to be insufficient. The article reviews the results of current studies on the use of cardiovascular drugs in the prevention of cardiotoxicity. Based on this knowledge, the most promising cardioprotective drugs seem to be carvedilol, nebivolol, enalapril, and candesartan, as they prevent heart remodeling and correct elevated resting heart rate, which directly affects mortality. Alternatively, in case of adverse reactions, statins might be considered. |
format | Online Article Text |
id | pubmed-6743633 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-67436332019-09-27 Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence Korzeniowska, Katarzyna Jankowski, Jerzy Cieślewicz, Artur Jabłecka, Anna Ther Clin Risk Manag Review Cardiovascular diseases and cancer are the most common death causes in the USA and Europe. Moreover, many patients suffer from both of these conditions – a situation which may result from cardiotoxicity of anticancer treatment. In order to reduce the severity of this adverse effect, various methods have been proposed, including the usage of new drug forms and less toxic analogs, omitting the combinations of potentially cardiotoxic drugs and introducing potential cardioprotective agents to the therapy. However, prevention of cardiotoxicity still seems to be insufficient. The article reviews the results of current studies on the use of cardiovascular drugs in the prevention of cardiotoxicity. Based on this knowledge, the most promising cardioprotective drugs seem to be carvedilol, nebivolol, enalapril, and candesartan, as they prevent heart remodeling and correct elevated resting heart rate, which directly affects mortality. Alternatively, in case of adverse reactions, statins might be considered. Dove 2019-09-09 /pmc/articles/PMC6743633/ /pubmed/31564887 http://dx.doi.org/10.2147/TCRM.S215857 Text en © 2019 Korzeniowska et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Korzeniowska, Katarzyna Jankowski, Jerzy Cieślewicz, Artur Jabłecka, Anna Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence |
title | Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence |
title_full | Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence |
title_fullStr | Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence |
title_full_unstemmed | Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence |
title_short | Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence |
title_sort | is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743633/ https://www.ncbi.nlm.nih.gov/pubmed/31564887 http://dx.doi.org/10.2147/TCRM.S215857 |
work_keys_str_mv | AT korzeniowskakatarzyna isitpossibletopreventchemotherapyinducedheartfailurewithcardiovasculardrugsthereviewofthecurrentclinicalevidence AT jankowskijerzy isitpossibletopreventchemotherapyinducedheartfailurewithcardiovasculardrugsthereviewofthecurrentclinicalevidence AT cieslewiczartur isitpossibletopreventchemotherapyinducedheartfailurewithcardiovasculardrugsthereviewofthecurrentclinicalevidence AT jabłeckaanna isitpossibletopreventchemotherapyinducedheartfailurewithcardiovasculardrugsthereviewofthecurrentclinicalevidence |